Emergent Biosolutions Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.8%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.36next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenues Quarterly156.1MTarget: 720000000 to 760000000
Adjusted EBITDA Quarterly35.6MTarget: 135000000 to 155000000
Watch Items
- NARCAN Franchise ErosionTrigger: Naloxone gross margin falling below 15% or significant market share loss to generic competitorsAction: Accelerate commercialization of Kloxxado in Canada and optimize OTC retail distribution channels
- Government Procurement and Contract ModificationsTrigger: Failure to secure renewals or modifications for key biodefense products (e.g., BAT, ACAM2000, BioThrax)Action: Engage with BARDA and the Department of Defense to align stockpiling requirements and secure contract extensions
Research as of 19 Jun 2026